Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
MORE FILTERS
’21e-‘22e ARR up by ~8% and adj. EBITDA up by ~2-4% Strong organic growth and attractive M&A roll-up story We reiterate BUY and our TP of NOK 17
Net leverage of 4.8x on credit-accretive M&A in Q1’21 Goal of becoming the European consolidator... …which could result in the leverage creeping back up
ARR as pre-announced, +4% org. ARR growth q-o-q Recognized revenues above, adj. EBITDA below ’20 PF figures supportive for consensus ’21 estimates
Big potential in rheumatoid arthritis and beyond We initiate with BUY and TP of SEK 72
’20-‘22e ARR +52-55%, ’21-‘22e EBITDA +113-115% Potential for NOK 1bn in sales and +40% EBITDA margin We reiterate BUY with a new TP of NOK 17 (13)
ARR and sales est. unchanged, but ’22e EBITDA +4% ARR could grow 60-70% through cross-selling BUY, with an unchanged TP of NOK 13
Q3 ARR in-line with ABGSC, higher org. ARR growth Adj. EBITDA slightly below on higher costs Strong growth to continue in Q4, limited est. changes
Alfa Laval Post-results: Food (and water) for thought Q3 leads to positive estimate revisions Stock down to attractive levels in absolute terms – BUY
Market-leading digital marketplace for public tenders Strong growth potential from upselling and M&A We initiate with a BUY recommendation, TP NOK 13
Save your current filters as a new Interest
Would you like to receive real-time email alerts when a new report is published under this interest?
These search results will show up under 'Saved searches' in the left panel
Would you like to receive real-time email when a new report matches this search?
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.